Lantern Pharma Inc. held its 2025 Annual Meeting of Stockholders on September 19, 2025. During the meeting, stockholders voted on several proposals. All six nominated directors, Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein, were elected to the board of directors. The proposal to approve a one-time repricing of certain stock options under the Lantern Pharma Inc. 2018 Equity Incentive Plan was approved. Additionally, the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-014652), on September 23, 2025, and is solely responsible for the information contained therein.
Comments